Hutchmed Share Price (HCM)

Lot off media coverage recently China biotech, story covering the hurdles faced by some Chinese frms.

'Chinese companies now account for about half of all global biotechnology business development deals, including out-licensing agreements, according to Citic Securities. Beijing has identified biotechnology as a strategic industry to help drive economic growth.'

SCMP

U.K. pharmaceutical group GSK has entered an agreement to acquire U.S.-based specialist oncology biotech Nuvalent for $10.6 billion.

CNBC

This is the share option scheme for next 10 (!) years, so the dilution for shareholders is acceptable.

the mandate to the board is pretty flexible: it can decide persons, performance criteria, holding period.

Interesting read for anyone invested in Chinese pharma, certainly paints a better picture than we are currently seeing with depressed share prices.

-------------------

'A boom in outlicensing agreements leads to a debate over which Chinese firms may be first to break into overseas markets with own brands

A handful of Chinese biotechnology companies are expected to bring medications to consumers in Europe and the US under their own brand names within the next 10 to 15 years, according to policy and industry analysts.'

Source: SCMP

Hutchmed also mentioned Ai in last update, R & D budget is by far the biggest slice of expenditure plus expediting the research process could speed things up and maybe lessen the chances of regulator push-back/rejection:

'AstraZeneca CEO Pascal Soriot said artificial intelligence is helping the company develop medicines faster, identify promising drug targets, and improve the odds of success in costly clinical trials.'

Source: CNBC